1 In 4 Gulf War Veterans Suffer From Illness Caused By Toxic Exposure At least one in four of the 697,000 U.S. veterans of the 1991 Gulf War suffer from Gulf War illness, a condition caused by exposure to toxic chemicals, including pesticides and a drug administered to protect troops against nerve gas, and no effective treatments have yet been found, a federal panel of scientific experts and veterans concludes in a landmark report released Monday.
Source: www.medicalnewstoday.com8,000 Pharmaceutical Scientists To Gather In Atlanta For The American Association Of Pharmaceutical Scientists' Annual Meeting And Exposition On November 16-20, 2008, 8,000 of the world's most prominent pharmaceutical scientists will put their best research on paper and present their findings at the AAPS Annual Meeting and Exposition. This year's meeting will take place in Atlanta at the Georgia World Congress Center.
Source: www.medicalnewstoday.comCooling The Brain Prevents Cell Death In Young Mice Exposed To Anesthesia New research from Washington University School of
Medicine in St. Louis suggests cooling the brain may prevent the death of nerve cells that has been observed in infant mice exposed to anesthesia. The effects of anesthesia on human infants and young children have been debated among neuroscientists, but growing evidence suggests exposure to anesthetic
drugs during brain development may contribute to behavioral and developmental delays.
Source: www.medicalnewstoday.comFREEDOM-C Trial Of Oral Treprostinil In Pulmonary Arterial Hypertension Fails To Meet Primary Endpoint United Therapeutics Corporation (Nasdaq: UTHR) announced the results of the FREEDOM-C trial of oral treprostinil, a sustained-release formulation of treprostinil, in pulmonary arterial hypertension (PAH). Preliminary analysis demonstrates that the trial did not achieve statistical significance for the primary endpoint, six minute walk (6MW) distance at Week 16.
Source: www.medicalnewstoday.comChronic Plaque Psoriasis - 2nd Case Of Progressive Multifocal Leukoencephalopathy In A Raptiva Patient Genentech, Inc. (NYSE:DNA) announced today that the company has issued a Dear
Healthcare Provider letter to inform dermatologists and neurologists of a 2nd case of progressive multifocal leukoencephalopathy (PML) which resulted in the death of a 73-year old woman who had received Raptiva® (efalizumab) for approximately four years for treatment of chronic plaque psoriasis.
Source: www.medicalnewstoday.comGeneThera Releases Results From Initial Animal Tests Of E.Coli O157:h7 Vaccine Amid News Of Increase Of E.Coli Discoveries In Beef Products GeneThera, Inc. (Pink Sheets: GTHR), released information about its E.Coli O157:H7 vaccine. The vaccine consists of Live Attenuated Bacterial Vaccine to Reduce or Inhibit Carriage and Shedding of Enterohemorrihagic Escherichia Coli in Cattle. This vaccine was developed for use against Shiga toxin-producing E.Coli (STEC) in cattle. This strategy is to construct mutants that have deletion in the genes responsible for E.Coli O157:H7 toxicity.
Source: www.medicalnewstoday.comFDA Clears The DPL (Deep Penetrating Light) Therapy System For Over-the-Counter - Home Use LED Technologies, LLC announced today that the U.S. Food and Drug Administration (FDA) cleared their DPL™ Therapy System for the relaxation of muscles and relief of muscle spasms, temporary relief of minor muscle and joint aches, pains and stiffness; temporary relief of minor pain and stiffness associated with arthritis; and to temporarily increase local blood circulation.
Source: www.medicalnewstoday.comGrape Powder Alleviates Joint Inflammation - Constituents In Grapes Have Antihyperalgesic Effects In A Rat Model Of Joint Inflammation Johns Hopkins Researchers at Neuroscience 2008 - Table grapes are high in flavonoids, which are thought to have strong antioxidant and anti-inflammatory properties. Now, researchers at the Johns Hopkins University School of
Medicine have shown that powdered grapes appear to reduce pain and inflammation in a rat model of arthritis, where rats knees are inflamed using a chemical injection.
Source: www.medicalnewstoday.comEGFR-Targeting Antibody Licensed To Abbott The international Ludwig Institute for Cancer Research (LICR) has announced that one of its spin-off companies, Life Science Pharmaceuticals, has licensed its lead cancer therapy candidate, antibody 806, to pharmaceutical company Abbott. The 806 antibody targets the EGFR cell surface protein but - crucially - only when the protein is over-expressed (over-produced) in cancer. Overexpression of EGFR occurs in more than 50% of some types of cancers.
Source: www.medicalnewstoday.comPrometheus Presents New Clinical Insights Into Diagnosis Of Crohn's Disease In Children From Analysis Of PROMETHEUS(R) IBD Serology 7 Test Results Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced new findings regarding the correlation between serologic markers and the diagnostic predictions of children with Crohn's disease following an analysis of PROMETHEUS(R) IBD Serology 7 test results.
Source: www.medicalnewstoday.com
# posted by Network @ 3:00 PM
